Navigation Links
Signalife Sees Accretive Purchase and Financial Commitments
Date:3/17/2008

LOS ANGELES, March 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced earlier today that it has received several formal purchase and financial commitments with respect to acquisitions of the Company's technology licenses, devices and services. These commitments have come internationally, including in Japan, other parts of Asia and Europe, as well as domestically.

Dr. Harmison, the Company's President and CEO, stated: "I anticipate closing these transactions in the upcoming two to four weeks, which comprise significant business for the Company. With the experiential base developed during my tenure regarding the ECG data generated from the usage of our technologies -- not only by health care providers but also through numerous Athletes for Life-sponsored mobile health care screenings -- there are now numerous additional revenue streams that have naturally become available to the Company. Indeed, physicians have provided me with a variety of data and information following very successful screenings this past weekend on the Athletes for Life Mobile Health Center in Temecula, California. With this kind of data garnered from real patients in the field, the foundation for the expansion of our life-saving devices becomes stronger every day."

The Company did not state the exact amount of business contemplated by these developments, and it cautioned that there is no certainty that any of the transactions will close as contemplated -- or at all.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Wins Second Frost & Sullivan Technology Award
2. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
5. U.S. Patent 7,299,083 Awarded to Signalife
6. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
7. Signalife Continues to Procure Purchase Orders, Revenues
8. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
9. Signalife Receives Another $3.3 Million Sales Orders
10. Signalife Achieves $1.98 Million Sales Orders Thus Far
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):